AGÕæÈ˹ٷ½

STOCK TITAN

[S-8] Cytokinetics Inc. Employee Benefit Plan Registration

Filing Impact
(No impact)
Filing Sentiment
(Neutral)
Form Type
S-8
Rhea-AI Filing Summary

Corebridge Financial (NYSE: CRBG) filed a Rule 424(b)(7) prospectus for a secondary offering of 30 million shares—about 5.6 % of outstanding stock—being sold exclusively by American International Group (AIG). The shares are priced at $33.65, implying gross proceeds of $1.01 billion to AIG and no cash to Corebridge. Morgan Stanley is sole underwriter and has a 30-day option to purchase up to 4.5 million additional shares for overallotments. If fully exercised, AIG’s ownership will fall to 14.74 % from 21.15 %; without the option it drops to 15.58 %. Blackstone and Nippon Life will continue to hold 11.51 % and 22.65 %, respectively.

The filing stresses that Corebridge is not issuing new shares, so there is no dilution. The company reiterates its $0.24 quarterly cash dividend (next payable 30 Sep 2025) and its expanded $5 billion share-repurchase authorization, of which $3.9 billion remains after buying back 4.5 million shares for $159 million in July � Aug 2025.

Key risk factors include market volatility from the block sale, continuing overhang from AIG’s remaining stake, and general insurance-industry exposures. Delivery of the shares is expected on 8 Aug 2025.

Corebridge Financial (NYSE: CRBG) ha depositato un prospetto ai sensi della Regola 424(b)(7) per un'offerta secondaria di 30 milioni di azioni—circa il 5,6% del capitale sociale in circolazione—vendute esclusivamente da American International Group (AIG). Le azioni sono quotate a 33,65 dollari, con un ricavo lordo stimato di 1,01 miliardi di dollari per AIG e nessun incasso per Corebridge. Morgan Stanley è l'unico sottoscrittore e dispone di un'opzione di 30 giorni per acquistare fino a 4,5 milioni di azioni aggiuntive per coprire eventuali eccedenze. Se l'opzione verrà esercitata completamente, la quota di AIG scenderà al 14,74% dal 21,15%; senza l'opzione, la quota si riduce al 15,58%. Blackstone e Nippon Life manterranno rispettivamente l'11,51% e il 22,65%.

Il deposito sottolinea che Corebridge non sta emettendo nuove azioni, quindi non vi sarà diluizione. La società conferma il suo dividendo trimestrale in contanti di 0,24 dollari (prossimo pagamento il 30 settembre 2025) e la sua estesa autorizzazione al riacquisto di azioni per 5 miliardi di dollari, di cui rimangono 3,9 miliardi dopo il riacquisto di 4,5 milioni di azioni per 159 milioni di dollari tra luglio e agosto 2025.

I principali fattori di rischio includono la volatilità del mercato dovuta alla vendita in blocco, la pressione continua derivante dalla quota residua di AIG e l'esposizione generale all'industria assicurativa. La consegna delle azioni è prevista per l'8 agosto 2025.

Corebridge Financial (NYSE: CRBG) presentó un prospecto bajo la Regla 424(b)(7) para una oferta secundaria de 30 millones de acciones—aproximadamente el 5,6 % del capital en circulación—vendidas exclusivamente por American International Group (AIG). Las acciones están valoradas en 33,65 dólares, lo que implica ingresos brutos de 1.010 millones de dólares para AIG y sin efectivo para Corebridge. Morgan Stanley es el único suscriptor y tiene una opción de 30 días para comprar hasta 4,5 millones de acciones adicionales para sobresuscripciones. Si se ejerce completamente, la participación de AIG caerá al 14,74 % desde el 21,15 %; sin la opción, baja al 15,58 %. Blackstone y Nippon Life continuarán manteniendo el 11,51 % y el 22,65 %, respectivamente.

El documento destaca que Corebridge no está emitiendo nuevas acciones, por lo que no hay dilución. La empresa reitera su dividendo trimestral en efectivo de 0,24 dólares (próximo pago el 30 de septiembre de 2025) y su ampliada autorización para recomprar acciones por 5.000 millones de dólares, de los cuales quedan 3.900 millones tras recomprar 4,5 millones de acciones por 159 millones de dólares entre julio y agosto de 2025.

Los principales factores de riesgo incluyen la volatilidad del mercado debido a la venta en bloque, la presión continua por la participación restante de AIG y la exposición general a la industria de seguros. La entrega de las acciones está prevista para el 8 de agosto de 2025.

Corebridge Financial (NYSE: CRBG)ëŠ� American International Group (AIG)ì� ë…ì ì ìœ¼ë¡� íŒë§¤í•˜ëŠ” 3,000ë§� ì£�, ì¦� 발행 주ì‹ì� ì•� 5.6%ì—� 해당하는 2ì°� 공모ë¥� 위한 Rule 424(b)(7) 설명서를 제출했습니다. 주당 ê°€ê²©ì€ 33.65달러ë¡� AIGì—� ì•� 10ì–� 1천만 달러ì� ì´ìˆ˜ìµì„ ì˜ë¯¸í•˜ë©° Corebridgeì—는 현금ì� 입금ë˜ì§€ 않습니다. Morgan Stanleyê°€ ë‹¨ë… ì¸ìˆ˜ì¸ìœ¼ë¡� 30ì� ë™ì•ˆ 최대 450ë§� 주를 추가 매입í•� ìˆ� 있는 옵션ì� 보유하고 있습니다. 옵션ì� ì „ë¶€ 행사ë� 경우 AIGì� ì§€ë¶„ì€ 21.15%ì—서 14.74%ë¡� ê°ì†Œí•˜ë©°, 옵션 미행ì‚� ì‹� 15.58%ë¡� 하ë½í•©ë‹ˆë‹�. Blackstoneê³� Nippon LifeëŠ� ê°ê° 11.51%와 22.65%ì� ì§€ë¶„ì„ ê³„ì† ë³´ìœ í•©ë‹ˆë‹�.

제출 서류ëŠ� Corebridgeê°€ 신주ë¥� 발행하지 않기 때문ì—� í¬ì„ 효과가 ì—†ìŒì� 강조합니ë‹�. 회사ëŠ� 분기ë³� 현금 배당ê¸� 0.24달러(ë‹¤ìŒ ì§€ê¸‰ì¼ 2025ë…� 9ì›� 30ì�)와 50ì–� 달러 규모ì� ì£¼ì‹ ìž¬ë§¤ìž� ìŠ¹ì¸ í•œë„ í™•ëŒ€ë¥� 재확ì¸í–ˆìœ¼ë©°, 2025ë…� 7월부í„� 8월까지 450ë§� 주를 1ì–� 5,900ë§� 달러ì—� 재매입한 í›� 39ì–� 달러가 남아 있습니다.

주요 위험 요소로는 대ëŸ� 매ë„ì—� 따른 시장 ë³€ë™ì„±, AIGì� 잔여 ì§€ë¶„ì— ëŒ€í•� ì§€ì†ì ì� ë¶€ë‹�, ë³´í—˜ ì‚°ì—… ì „ë°˜ì� 노출 ë“±ì´ í¬í•¨ë©ë‹ˆë‹�. ì£¼ì‹ ì¸ë„ëŠ� 2025ë…� 8ì›� 8ì¼ë¡œ 예정ë˜ì–´ 있습니다.

Corebridge Financial (NYSE : CRBG) a déposé un prospectus selon la règle 424(b)(7) pour une offre secondaire de 30 millions d’actions—environ 5,6 % du capital en circulation—vendues exclusivement par American International Group (AIG). Les actions sont proposées à 33,65 dollars, ce qui implique un produit brut d’environ 1,01 milliard de dollars pour AIG, sans apport de liquidités pour Corebridge. Morgan Stanley est le seul souscripteur et dispose d’une option de 30 jours pour acheter jusqu’� 4,5 millions d’actions supplémentaires en cas de surallocation. Si l’option est entièrement exercée, la participation d’AIG passera de 21,15 % à 14,74 % ; sans l’option, elle descend à 15,58 %. Blackstone et Nippon Life continueront de détenir respectivement 11,51 % et 22,65 %.

Le dépôt insiste sur le fait que Corebridge n’émet pas de nouvelles actions, il n’y a donc pas de dilution. La société réaffirme son dividende trimestriel en espèces de 0,24 $ (prochain versement le 30 septembre 2025) ainsi que son autorisation élargie de rachat d’actions de 5 milliards de dollars, dont 3,9 milliards restent disponibles après le rachat de 4,5 millions d’actions pour 159 millions de dollars entre juillet et août 2025.

Les principaux facteurs de risque comprennent la volatilité du marché liée à la vente en bloc, la pression persistante due à la participation résiduelle d’AIG et les expositions générales au secteur des assurances. La livraison des actions est prévue pour le 8 août 2025.

Corebridge Financial (NYSE: CRBG) hat einen Rule 424(b)(7)-Prospekt für ein Sekundärangebot von 30 Millionen Aktien � etwa 5,6 % des ausstehenden Aktienkapitals � eingereicht, die ausschließlich von American International Group (AIG) verkauft werden. Die Aktien sind zu 33,65 US-Dollar bewertet, was für AIG Bruttoerlöse von 1,01 Milliarden US-Dollar bedeutet und Corebridge keinen Erlös bringt. Morgan Stanley ist alleiniger Underwriter und hat eine 30-tägige Option, bis zu 4,5 Millionen zusätzliche Aktien für Überzuteilungen zu kaufen. Wird die Option vollständig ausgeübt, sinkt AIGs Anteil von 21,15 % auf 14,74 %; ohne die Option fällt er auf 15,58 %. Blackstone und Nippon Life halten weiterhin 11,51 % bzw. 22,65 %.

Die Einreichung betont, dass Corebridge keine neuen Aktien ausgibt, sodass keine Verwässerung eintritt. Das Unternehmen bekräftigt seine vierteljährliche Bardividende von 0,24 US-Dollar (nächste Zahlung am 30. September 2025) und seine erweiterte Aktienrückkaufgenehmigung in Höhe von 5 Milliarden US-Dollar, von der nach dem Rückkauf von 4,5 Millionen Aktien für 159 Millionen US-Dollar im Juli–August 2025 noch 3,9 Milliarden US-Dollar verbleiben.

Zu den wesentlichen Risikofaktoren zählen die Marktvolatilität durch den Blockverkauf, der anhaltende Überhang der verbleibenden AIG-Beteiligung sowie allgemeine Risiken der Versicherungsbranche. Die Lieferung der Aktien wird für den 8. August 2025 erwartet.

Positive
  • No dilution: shares come from AIG, leaving Corebridge’s EPS and capital ratios unaffected.
  • Expanded $5 billion repurchase plan with $3.9 billion still available offers downside support.
  • Consistent cash dividend of $0.24 per quarter signals stable cash generation.
  • AIG ownership falls, reducing legacy-parent influence and moving toward a cleaner float.
Negative
  • Technical supply pressure: 30 million shares (+ optional 4.5 million) may weigh on price short-term.
  • Overhang persists: AIG will still hold ~15 % (â‰�80 million shares) post-offering.
  • No primary proceeds: company gains no additional capital to deploy for growth or debt reduction.

Insights

TL;DR: Pure secondary sale—no dilution, but supply overhang persists and may pressure near-term price.

The transaction is strictly a liquidity event for AIG, shrinking its stake by ~5.6 pp and widening Corebridge’s float. Because Corebridge receives no proceeds, capital structure and EPS remain unchanged—fundamentally neutral. However, 30 million shares (~$1 billion) hitting the market can create technical weakness, especially given a 30-day lock-up that is relatively short. Management can offset some pressure via its large remaining $3.9 billion buy-back authority, which equates to roughly 14 % of current market cap at the $34 range. From an ECM standpoint, the filing re-opens the path for eventual full AIG exit, gradually reducing the control discount.

TL;DR: Dividend integrity and buy-back capacity are intact; yield investors see limited impact.

The deal neither affects payout capacity nor leverages the balance sheet. The steady $0.24 quarterly dividend (�2.8 % forward yield) and ongoing buy-backs remain the key return drivers. Reduced sponsor ownership lowers governance risk over time, a positive for long-term holders. Nonetheless, the sizeable free-float increase and residual 15 % AIG position maintain some overhang, warranting cautious sizing until supply is absorbed. Overall, fundamentals unchanged; market impact hinges on depth of demand and management’s buy-back pace.

Corebridge Financial (NYSE: CRBG) ha depositato un prospetto ai sensi della Regola 424(b)(7) per un'offerta secondaria di 30 milioni di azioni—circa il 5,6% del capitale sociale in circolazione—vendute esclusivamente da American International Group (AIG). Le azioni sono quotate a 33,65 dollari, con un ricavo lordo stimato di 1,01 miliardi di dollari per AIG e nessun incasso per Corebridge. Morgan Stanley è l'unico sottoscrittore e dispone di un'opzione di 30 giorni per acquistare fino a 4,5 milioni di azioni aggiuntive per coprire eventuali eccedenze. Se l'opzione verrà esercitata completamente, la quota di AIG scenderà al 14,74% dal 21,15%; senza l'opzione, la quota si riduce al 15,58%. Blackstone e Nippon Life manterranno rispettivamente l'11,51% e il 22,65%.

Il deposito sottolinea che Corebridge non sta emettendo nuove azioni, quindi non vi sarà diluizione. La società conferma il suo dividendo trimestrale in contanti di 0,24 dollari (prossimo pagamento il 30 settembre 2025) e la sua estesa autorizzazione al riacquisto di azioni per 5 miliardi di dollari, di cui rimangono 3,9 miliardi dopo il riacquisto di 4,5 milioni di azioni per 159 milioni di dollari tra luglio e agosto 2025.

I principali fattori di rischio includono la volatilità del mercato dovuta alla vendita in blocco, la pressione continua derivante dalla quota residua di AIG e l'esposizione generale all'industria assicurativa. La consegna delle azioni è prevista per l'8 agosto 2025.

Corebridge Financial (NYSE: CRBG) presentó un prospecto bajo la Regla 424(b)(7) para una oferta secundaria de 30 millones de acciones—aproximadamente el 5,6 % del capital en circulación—vendidas exclusivamente por American International Group (AIG). Las acciones están valoradas en 33,65 dólares, lo que implica ingresos brutos de 1.010 millones de dólares para AIG y sin efectivo para Corebridge. Morgan Stanley es el único suscriptor y tiene una opción de 30 días para comprar hasta 4,5 millones de acciones adicionales para sobresuscripciones. Si se ejerce completamente, la participación de AIG caerá al 14,74 % desde el 21,15 %; sin la opción, baja al 15,58 %. Blackstone y Nippon Life continuarán manteniendo el 11,51 % y el 22,65 %, respectivamente.

El documento destaca que Corebridge no está emitiendo nuevas acciones, por lo que no hay dilución. La empresa reitera su dividendo trimestral en efectivo de 0,24 dólares (próximo pago el 30 de septiembre de 2025) y su ampliada autorización para recomprar acciones por 5.000 millones de dólares, de los cuales quedan 3.900 millones tras recomprar 4,5 millones de acciones por 159 millones de dólares entre julio y agosto de 2025.

Los principales factores de riesgo incluyen la volatilidad del mercado debido a la venta en bloque, la presión continua por la participación restante de AIG y la exposición general a la industria de seguros. La entrega de las acciones está prevista para el 8 de agosto de 2025.

Corebridge Financial (NYSE: CRBG)ëŠ� American International Group (AIG)ì� ë…ì ì ìœ¼ë¡� íŒë§¤í•˜ëŠ” 3,000ë§� ì£�, ì¦� 발행 주ì‹ì� ì•� 5.6%ì—� 해당하는 2ì°� 공모ë¥� 위한 Rule 424(b)(7) 설명서를 제출했습니다. 주당 ê°€ê²©ì€ 33.65달러ë¡� AIGì—� ì•� 10ì–� 1천만 달러ì� ì´ìˆ˜ìµì„ ì˜ë¯¸í•˜ë©° Corebridgeì—는 현금ì� 입금ë˜ì§€ 않습니다. Morgan Stanleyê°€ ë‹¨ë… ì¸ìˆ˜ì¸ìœ¼ë¡� 30ì� ë™ì•ˆ 최대 450ë§� 주를 추가 매입í•� ìˆ� 있는 옵션ì� 보유하고 있습니다. 옵션ì� ì „ë¶€ 행사ë� 경우 AIGì� ì§€ë¶„ì€ 21.15%ì—서 14.74%ë¡� ê°ì†Œí•˜ë©°, 옵션 미행ì‚� ì‹� 15.58%ë¡� 하ë½í•©ë‹ˆë‹�. Blackstoneê³� Nippon LifeëŠ� ê°ê° 11.51%와 22.65%ì� ì§€ë¶„ì„ ê³„ì† ë³´ìœ í•©ë‹ˆë‹�.

제출 서류ëŠ� Corebridgeê°€ 신주ë¥� 발행하지 않기 때문ì—� í¬ì„ 효과가 ì—†ìŒì� 강조합니ë‹�. 회사ëŠ� 분기ë³� 현금 배당ê¸� 0.24달러(ë‹¤ìŒ ì§€ê¸‰ì¼ 2025ë…� 9ì›� 30ì�)와 50ì–� 달러 규모ì� ì£¼ì‹ ìž¬ë§¤ìž� ìŠ¹ì¸ í•œë„ í™•ëŒ€ë¥� 재확ì¸í–ˆìœ¼ë©°, 2025ë…� 7월부í„� 8월까지 450ë§� 주를 1ì–� 5,900ë§� 달러ì—� 재매입한 í›� 39ì–� 달러가 남아 있습니다.

주요 위험 요소로는 대ëŸ� 매ë„ì—� 따른 시장 ë³€ë™ì„±, AIGì� 잔여 ì§€ë¶„ì— ëŒ€í•� ì§€ì†ì ì� ë¶€ë‹�, ë³´í—˜ ì‚°ì—… ì „ë°˜ì� 노출 ë“±ì´ í¬í•¨ë©ë‹ˆë‹�. ì£¼ì‹ ì¸ë„ëŠ� 2025ë…� 8ì›� 8ì¼ë¡œ 예정ë˜ì–´ 있습니다.

Corebridge Financial (NYSE : CRBG) a déposé un prospectus selon la règle 424(b)(7) pour une offre secondaire de 30 millions d’actions—environ 5,6 % du capital en circulation—vendues exclusivement par American International Group (AIG). Les actions sont proposées à 33,65 dollars, ce qui implique un produit brut d’environ 1,01 milliard de dollars pour AIG, sans apport de liquidités pour Corebridge. Morgan Stanley est le seul souscripteur et dispose d’une option de 30 jours pour acheter jusqu’� 4,5 millions d’actions supplémentaires en cas de surallocation. Si l’option est entièrement exercée, la participation d’AIG passera de 21,15 % à 14,74 % ; sans l’option, elle descend à 15,58 %. Blackstone et Nippon Life continueront de détenir respectivement 11,51 % et 22,65 %.

Le dépôt insiste sur le fait que Corebridge n’émet pas de nouvelles actions, il n’y a donc pas de dilution. La société réaffirme son dividende trimestriel en espèces de 0,24 $ (prochain versement le 30 septembre 2025) ainsi que son autorisation élargie de rachat d’actions de 5 milliards de dollars, dont 3,9 milliards restent disponibles après le rachat de 4,5 millions d’actions pour 159 millions de dollars entre juillet et août 2025.

Les principaux facteurs de risque comprennent la volatilité du marché liée à la vente en bloc, la pression persistante due à la participation résiduelle d’AIG et les expositions générales au secteur des assurances. La livraison des actions est prévue pour le 8 août 2025.

Corebridge Financial (NYSE: CRBG) hat einen Rule 424(b)(7)-Prospekt für ein Sekundärangebot von 30 Millionen Aktien � etwa 5,6 % des ausstehenden Aktienkapitals � eingereicht, die ausschließlich von American International Group (AIG) verkauft werden. Die Aktien sind zu 33,65 US-Dollar bewertet, was für AIG Bruttoerlöse von 1,01 Milliarden US-Dollar bedeutet und Corebridge keinen Erlös bringt. Morgan Stanley ist alleiniger Underwriter und hat eine 30-tägige Option, bis zu 4,5 Millionen zusätzliche Aktien für Überzuteilungen zu kaufen. Wird die Option vollständig ausgeübt, sinkt AIGs Anteil von 21,15 % auf 14,74 %; ohne die Option fällt er auf 15,58 %. Blackstone und Nippon Life halten weiterhin 11,51 % bzw. 22,65 %.

Die Einreichung betont, dass Corebridge keine neuen Aktien ausgibt, sodass keine Verwässerung eintritt. Das Unternehmen bekräftigt seine vierteljährliche Bardividende von 0,24 US-Dollar (nächste Zahlung am 30. September 2025) und seine erweiterte Aktienrückkaufgenehmigung in Höhe von 5 Milliarden US-Dollar, von der nach dem Rückkauf von 4,5 Millionen Aktien für 159 Millionen US-Dollar im Juli–August 2025 noch 3,9 Milliarden US-Dollar verbleiben.

Zu den wesentlichen Risikofaktoren zählen die Marktvolatilität durch den Blockverkauf, der anhaltende Überhang der verbleibenden AIG-Beteiligung sowie allgemeine Risiken der Versicherungsbranche. Die Lieferung der Aktien wird für den 8. August 2025 erwartet.

As filed with the Securities and Exchange Commission on August 7, 2025

Registration No. 333-   

 

 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM S-8

REGISTRATION STATEMENT

Under

The Securities Act of 1933

 

 

CYTOKINETICS, INCORPORATED

(Exact name of Registrant as specified in its charter)

 

 

 

Delaware   94-3291317

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification Number)

350 Oyster Point Boulevard

South San Francisco, CA 94080

(Address of principal executive offices)

 

 

AMENDED AND RESTATED 2004 EQUITY INCENTIVE PLAN

(Full title of the plan)

 

 

Robert I. Blum

President and Chief Executive Officer

Cytokinetics, Incorporated

350 Oyster Point Boulevard

South San Francisco, CA 94080

(650) 624-3000

(Name, address, and telephone number, including area code, of agent for service)

 

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer      Accelerated filer  
Non-accelerated filer      Smaller reporting company  
     Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

 

 
 


EXPLANATORY NOTE

This Registration Statement on Form S-8 is being filed for the purpose of registering an additional 5,000,000 shares of the Common Stock to be issued pursuant to the Amended and Restated 2004 Equity Incentive Plan (the “EIP”). The shares of the Common Stock previously reserved for issuance under the EIP were registered on the Registrant’s Registration Statements on Form  S-8 previously filed with the Securities and Exchange Commission (the “SEC”) on May 4, 2004 (File No. 333-115146), June 20, 2005 (File No.  333-125973), April 14, 2006 (File No.  333-133323), February  28, 2007 (File No. 333-140963), March 14, 2008 (File No. 333-149713), August 7, 2008 (File No.  333-152850), August 6, 2009 (File No.  333-161116), August 4, 2010 (File No.  333-168520), August 5, 2011 (File No.  333-176089), August 6, 2012 (File No.  333-183091), August 7, 2013 (File No.  333-190458), August  5, 2015 (File No. 333-206101), November 3, 2017 (File No. 333-221348), March 4, 2020 (File No.  333-236889), May 29, 2020 (File No.  333-238786), May 13, 2021 (File No.  333-256054), November 5, 2021 (File No.  333-260840), May 31, 2022 (File No.  333-265316), and March 1, 2023 (File No. 333-270182), (collectively, the “Prior Registration Statements”).

This Registration Statement on Form S-8 relates to securities of the same class as that to which the Prior Registration Statements relate, and is submitted in accordance with General Instruction E to Form S-8 regarding Registration of Additional Securities. Pursuant to General Instruction E of Form S-8, the contents of the Prior Registration Statements, to the extent relating to the registration of Common Stock issuable under the EIP are incorporated herein by reference and made part of this Registration Statement, except as amended hereby.

ITEM 8. EXHIBITS

 

Exhibit

Number

  Description
 4.1(1)   Amended and Restated Certificate of Incorporation.
 4.2(2)   Amended and Restated Bylaws.
 4.3(3)   Certificate of Amendment of Amended and Restated Certificate of Incorporation.
 4.4(4)   Certificate of Amendment of Amended and Restated Certificate of Incorporation.
 4.5(5)   Certificate of Amendment of Amended and Restated Certificate of Incorporation.
 4.6(6)   Certificate of Amendment of Amended and Restated Certificate of Incorporation.
 4.7*   Certificate of Amendment of Amended and Restated Certificate of Incorporation
 4.8(7)   Specimen Common Stock Certificate.
 5.1*   Opinion of Cooley LLP.
23.1*   Consent of Independent Registered Public Accounting Firm.
23.2*   Consent of Cooley LLP (included in Exhibit 5.1).
24.1*   Power of Attorney (included on the signature page of this Form S-8).
99.1(8)   Amended and Restated 2004 Equity Incentive Plan.
107*   Filing Fee Table.

 

*

Filed herewith

(1)

Incorporated by reference to Exhibit 3.1 to the Company’s registration statement on Form S-3, registration number 333-174869, filed with the Securities and Exchange Commission on June 13, 2011.

(2)

Incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on November 17, 2023.

(3)

Incorporated by reference to Exhibit 3.2 to the Company’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on August 4, 2011.

(4)

Incorporated by reference to Exhibit 5.1 to the Company’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on June 25, 2013.

(5)

Incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on May 20, 2016.

(6)

Incorporated by reference to Exhibit 3.5 to the Company’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on August 3, 2023.

(7)

Incorporated by reference to Exhibit 4.1 to the Company’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on May 9, 2007.

(8)

Incorporated by reference to Appendix A of the Company’s definitive proxy statement, filed with the Securities and Exchange Commission on April 10, 2025.


SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of South San Francisco, State of California, on this seventh day of August, 2025.

 

CYTOKINETICS, INCORPORATED
By:  

/s/ Robert I. Blum

  Robert I. Blum
 

President and Chief Executive Officer

(Principal Executive Officer)

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Robert I. Blum, Sung Lee and John Faurescu jointly and severally, as his or her attorneys-in-fact, with full power of substitution in each, for him or her in any and all capacities to sign any amendments to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that each of said attorneys-in-fact, or his or her substitutes, may do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed below by the following persons in the capacities and on the dates indicated.


Signature    Title    Date

/s/ Robert I. Blum

     
Robert I. Blum   

President, Chief Executive Officer and Director

(Principal Executive Officer)

   August 7, 2025

/s/ Sung Lee

     
Sung Lee   

Executive Vice President, Chief Financial Officer

(Principal Financial Officer and Principal Accounting Officer)

   August 7, 2025

/s/ John T. Henderson

   Chairman of the Board of Directors    August 7, 2025
John T. Henderson, M.B., Ch. B.      

/s/ Muna Bhanji

   Director    August 7, 2025
Muna Bhanji      

/s/ Robert A. Harrington

   Director    August 7, 2025
Robert A. Harrington, M.D.      

/s/ Edward M. Kaye

   Director    August 7, 2025
Edward M. Kaye, M.D.      

/s/ Robert E. Landry

   Director    August 7, 2025
Robert E. Landry      

/s/ B. Lynne Parshall

   Director    August 7, 2025
B. Lynne Parshall, Esq.      

/s/ Wendell Wierenga

   Director    August 7, 2025
Wendell Wierenga, Ph. D.      

/s/ Nancy J. Wysenski

   Director    August 7, 2025
Nancy J. Wysenski      

FAQ

How many Corebridge (CRBG) shares are being sold in this offering?

AIG is selling 30 million shares, with an option for the underwriter to buy an additional 4.5 million.

Does Corebridge receive any proceeds from the sale?

No. All ~$1.01 billion in gross proceeds go to AIG, the selling shareholder.

Will existing shareholders be diluted?

No dilution; the shares are already outstanding and are transferred from AIG to public investors.

What will AIG’s ownership be after the transaction?

Approximately 15.58 % (or 14.74 % if the 4.5 millionâ€share option is fully exercised).

What is Corebridge’s current dividend policy?

The company pays a $0.24 quarterly cash dividend; the next payment is scheduled for 30 Sep 2025.

How much capacity remains under the share-repurchase program?

About $3.9 billion is still authorized following recent buy-backs.
Cytokinetics Inc

NASDAQ:CYTK

CYTK Rankings

CYTK Latest News

CYTK Latest SEC Filings

CYTK Stock Data

4.32B
116.10M
0.7%
120.29%
13.34%
Biotechnology
Pharmaceutical Preparations
United States
SOUTH SAN FRANCISCO